Genenta Science Has Dosed First Of Three Patients In Cohort 8 (Temferon At 4X10^6/Kg), The Last Cohort Of Phase 1 Dose-ranging Part Of Phase 1/2 Trial In Newly Diagnosed UMGMT Glioblastoma Multiforme Patients; Top Line Data Expected By End Of 2Q24
Genenta Science Has Dosed First Of Three Patients In Cohort 8 (Temferon At 4X10^6/Kg), The Last Cohort Of Phase 1 Dose-ranging Part Of Phase 1/2 Trial In Newly Diagnosed UMGMT Glioblastoma Multiforme Patients; Top Line Data Expected By End Of 2Q24
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.